patient subgroup...
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
favipiravir - versus control - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.69 [0.28, 1.68]< 1 0% 1 study (1/-) 79.1 % NA not evaluable crucial - deaths 0.91 [0.45, 1.86]< 1 0% 5 studies (6/-) 60.1 % some concern not evaluable moderate crucial - clinical improvement 1.65 [1.28, 2.13]> 1 0% 5 studies (5/-) 100.0 % some concern not evaluable moderate important - clinical improvement (14-day) 1.26 [1.04, 1.53]> 1 0% 3 studies (3/-) 99.0 % some concern not evaluable moderate important - clinical improvement (28-day) 1.32 [0.86, 2.03]> 1 70% 2 studies (2/-) 89.4 % some concern not evaluable moderate important - clinical improvement (7-day) 1.62 [1.15, 2.28]> 1 0% 2 studies (2/-) 99.7 % some concern not evaluable moderate important - clinical improvement (time to event analysis only) 1.33 [0.93, 1.90]> 1 71% 4 studies (5/-) 94.0 % some concern not evaluable moderate important - hospital discharge 1.10 [0.69, 1.75]> 1 72% 2 studies (3/-) 65.7 % some concern not evaluable moderate important - hospitalization 0.12 [0.01, 2.26]< 1 0% 1 study (1/-) 92.0 % NA not evaluable important - mechanical ventilation 0.06 [0.01, 0.83]< 1 0% 1 study (1/-) 98.2 % NA not evaluable important - mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 1 0% 1 study (1/-) 98.2 % NA not evaluable important - viral clearance 1.75 [1.07, 2.87]> 1 63% 6 studies (7/-) 98.7 % some concern not evaluable moderate important - viral clearance (time to event analysis only) 1.32 [1.03, 1.69]> 1 0% 2 studies (3/-) 98.6 % some concern not evaluable moderate important - viral clearance by day 14 1.12 [0.48, 2.63]> 1 32% 3 studies (3/-) 60.4 % some concern not evaluable moderate important - viral clearance by day 7 1.44 [0.78, 2.65]> 1 61% 3 studies (3/-) 87.5 % some concern not evaluable moderate important - ICU admission 1.48 [0.83, 2.64]< 1 0% 2 studies (2/-) 9.1 % some concern not evaluable moderate non important - 00 serious adverse events 2.73 [0.55, 13.60]< 1 0% 4 studies (4/-) 11.1 % some concern not evaluable moderate important - adverse events 3.78 [1.07, 13.38]< 1 91% 4 studies (5/-) 2.0 % some concern not evaluable moderate non important -
LoD: level of statistical demonstration:
